Ovid Therapeutics (OVID) Invested Capital (2019 - 2021)

Ovid Therapeutics (OVID) has reported Invested Capital for 3 consecutive years, with $179.7 million the latest figure, recorded in Q4 2021.

• For the quarter ending Q4 2021, Invested Capital rose 290.21% year-over-year to $179.7 million; the trailing twelve-month figure through Dec 2021 stood at $179.7 million (up 290.21% YoY), and the FY2021 full-year result was $179.7 million, up 290.21% from the prior year.
• Invested Capital rose to $179.7 million in Q4 2021 per OVID's latest filing, from $46.1 million in the prior quarter.
• Across five years, Invested Capital topped out at $179.7 million in Q4 2021 and bottomed at $30.7 million in Q3 2019.
• Historically, Invested Capital has averaged $72.5 million across 3 years, with a median of $58.6 million in 2019.
• The sharpest annual moves came in 2020 and 2021: Invested Capital slumped 34.49% in 2020, then surged 290.21% in 2021.
• Over 3 years, Invested Capital stood at $70.3 million in 2019, then plunged by 34.49% to $46.1 million in 2020, then soared by 290.21% to $179.7 million in 2021.
• According to Business Quant data, Invested Capital over the past three periods registered $179.7 million, $46.1 million, and $63.9 million for Q4 2021, Q4 2020, and Q3 2020 respectively.